Effect of Multiple Doses of Omeprazole on the Pharmacokinetics, Safety, and Tolerability of Roxadustat in Healthy Subjects.

European Journal of Drug Metabolism and Pharmacokinetics
Dorien Groenendaal-van de MeentMarloes Schaddelee

Abstract

Roxadustat is an orally active hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of anemia in chronic kidney disease. This study investigated the effect of multiple daily oral doses of omeprazole on the pharmacokinetics, safety, and tolerability of a single oral dose of roxadustat. This phase 1, open-label, two-period, one-sequence, crossover study enrolled healthy subjects. During Period 1, subjects received a single oral dose of 100 mg roxadustat. After a ≥ 7-day washout, subjects started Period 2 and received daily oral doses of 40 mg omeprazole on Days 1-9, and a single oral dose of 100 mg roxadustat on Day 7. Roxadustat pharmacokinetics were assessed on Days 1-4 in Period 1 and on Days 7-10 in Period 2. Primary endpoints were area under the concentration-time profile from the time of dosing extrapolated to infinity (AUCinf) and maximum concentration (Cmax). Safety was assessed by vital signs, laboratory tests, electrocardiograms, and nature, frequency, and severity of treatment-emergent adverse events (TEAEs). Eighteen subjects were enrolled. The geometric least squares mean ratio for both AUCinf and Cmax of roxadustat (with omeprazole/alone) was 104.5%; 90% confidence intervals were within the no-eff...Continue Reading

References

Mar 10, 2009·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Karl Broich, UNKNOWN Committee for Medicinal Products for Human Use
Sep 1, 2012·Journal of the American Society of Nephrology : JASN·Jodie L Babitt, Herbert Y Lin
Jan 7, 2014·PloS One·Melissa E Stauffer, Tao Fan
Aug 5, 2015·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Anatole BesarabThomas B Neff
Oct 24, 2015·Journal of the American Society of Nephrology : JASN·Anatole BesarabThomas B Neff
Apr 21, 2016·Clinical Journal of the American Society of Nephrology : CJASN·Robert ProvenzanoThomas B Neff
Jan 25, 2017·American Journal of Nephrology·Francesco LocatelliIain C Macdougall
Mar 1, 2017·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Nupur Gupta, Jay B Wish
Apr 4, 2017·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Nan ChenFrank H Valone

❮ Previous
Next ❯

Methods Mentioned

BETA
glucosidation
pregnancy test

Software Mentioned

Phoenix

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.